Clinical Trial Update: A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies [Phase 1]

View source ↗

Summary

This Phase 1 safety study evaluates the combination of sunitinib and pemetrexed in patients with advanced solid malignancies to assess safety and tolerability; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Neoplasms

Drugs mentioned

• Alimta (pemetrexed)
• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Neoplasm, Malignant | Phase 1 | Status: COMPLETED | Results posted: 2010-11-25